Chemokine interaction with synergy-inducing molecules: Fine tuning modulation of cell trafficking

Journal of Leukocyte Biology

Volumn 99, Issue 6, 2016, Pages 851-855

  Cecchinato, Valentina ^a   D’Agostino, Gianluca ^a   Raeli, Lorenzo ^a   Uguccioni, Mariagrazia ^a  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

Author keywords

Cell migration; Chemokine activities; CXCL12; HMGB1

Indexed keywords

ALARMIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; STROMAL CELL DERIVED FACTOR 1; MULTIPROTEIN COMPLEX;

CELL ACTIVITY; CELL MIGRATION; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CELL MOTION; METABOLISM;

ANIMALS; CELL MOVEMENT; CHEMOKINES; HMGB1 PROTEIN; HUMANS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES;

EID: 84971384429     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1MR1015-457R     Document Type: Review

References (64)

1. Charo, I. F., Ransohoff, R. M. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621.
2. Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., Mantovani, A., Matsushima, K., Murphy, P. M., Nibbs, R., Nomiyama, H., Power, C. A., Proudfoot, A. E., Rosenkilde, M. M., Rot, A., Sozzani, S., Thelen, M., Yoshie, O., Zlotnik, A. (2014) International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors [corrected]. Pharmacol. Rev. 66, 1-79.
3. Mazzucchelli, L., Blaser, A., Kappeler, A., Schärli, P., Laissue, J. A., Baggiolini, M., Uguccioni, M. (1999) BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J. Clin. Invest. 104, R49-R54.
4. Uguccioni, M., Gionchetti, P., Robbiani, D. F., Rizzello, F., Peruzzo, S., Campieri, M., Baggiolini, M. (1999) Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol. 155, 331-336.
5. Agace, W. W., Amara, A., Roberts, A. I., Pablos, J. L., Thelen, S., Uguccioni, M., Li, X. Y., Marsal, J., Arenzana-Seisdedos, F., Delaunay, T., Ebert, E. C., Moser, B., Parker, C. M. (2000) Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr. Biol. 10, 325-328.
6. Smith, J. R., Braziel, R. M., Paoletti, S., Lipp, M., Uguccioni, M., Rosenbaum, J. T. (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101, 815-821.
7. Manzo, A., Paoletti, S., Carulli, M., Blades, M. C., Barone, F., Yanni, G., Fitzgerald, O., Bresnihan, B., Caporali, R., Montecucco, C., Uguccioni, M., Pitzalis, C. (2005) Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347-1359.
8. Wells, T. N., Power, C. A., Shaw, J. P., Proudfoot, A. E. (2006) Chemokine blockers—therapeutics in the making? Trends Pharmacol. Sci. 27, 41-47.
9. Yokoyama, W., Kohsaka, H., Kaneko, K., Walters, M., Takayasu, A., Fukuda, S., Miyabe, C., Miyabe, Y., Love, P. E., Nakamoto, N., Kanai, T., Watanabe-Imai, K., Charvat, T. T., Penfold, M. E., Jaen, J., Schall, T. J., Harigai, M., Miyasaka, N., Nanki, T. (2014) Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res. Ther. 16, 445.
10. De Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J., Schall, T. J.; CCX140-B Diabetic Nephropathy Study Group. (2015) The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropthy: a randomised trial. Lancet Diabetes Endocrinol. 3, 687-696.
11. Panzer, U., Uguccioni, M. (2004) Prostaglandin E2 modulates the functional responsiveness of human monocytes to chemokines. Eur. J. Immunol. 34, 3682-3689.
12. Loos, T., Dekeyzer, L., Struyf, S., Schutyser, E., Gijsbers, K., Gouwy, M., Fraeyman, A., Put, W., Ronsse, I., Grillet, B., Opdenakker, G., Van Damme, J., Proost, P. (2006) TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab. Invest. 86, 902-916.
13. Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M., Uguccioni, M. (2001) Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97, 1920-1924.
14. Ogilvie, P., Paoletti, S., Clark-Lewis, I., Uguccioni, M. (2003) Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102, 789-794.
15. Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M., Gerber, B. (2004) Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5: a human chemokine with a regulatory role. J. Biol. Chem. 279, 23357-23363.
16. Petkovic, V., Moghini, C., Paoletti, S., Uguccioni, M., Gerber, B. (2004) I-TAC/CXCL11 is a natural antagonist for CCR5. J. Leukoc. Biol. 76, 701-708.
17. Fulkerson, P. C., Zimmermann, N., Brandt, E. B., Muntel, E. E., Doepker, M. P., Kavanaugh, J. L., Mishra, A., Witte, D. P., Zhang, H., Farber, J. M., Yang, M., Foster, P. S., Rothenberg, M. E. (2004) Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-g (Mig, CXCL9). Proc. Natl. Acad. Sci. U.S.A. 101, 1987-1992.
18. Mellado, M., Rodrìguez-Frade, J. M., Vila-Coro, A. J., Fernández, S., Martìn de Ana, A., Jones, D. R., Torán, J. L., Martìnez, A. C. (2001) Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497-2507.
19. Krug, A., Uppaluri, R., Facchetti, F., Dorner, B. G., Sheehan, K. C., Schreiber, R. D., Cella, M., Colonna, M. (2002) IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J. Immunol. 169, 6079-6083.
20. Vanbervliet, B., Bendriss-Vermare, N., Massacrier, C., Homey, B., de Bouteiller, O., Brière, F., Trinchieri, G., Caux, C. (2003) The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med. 198, 823-830.
21. Gouwy, M., Struyf, S., Noppen, S., Schutyser, E., Springael, J. Y., Parmentier, M., Proost, P., Van Damme, J. (2008) Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol. Pharmacol. 74, 485-495.
22. Gouwy, M., Struyf, S., Berghmans, N., Vanormelingen, C., Schols, D., Van Damme, J. (2011) CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. Eur. J. Immunol. 41, 963-973.
23. Gouwy, M., Schiraldi, M., Struyf, S., Van Damme, J., Uguccioni, M. (2012) Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. Immunol. Lett. 145, 10-14.
24. Fernando, H., Chin, C., Rösgen, J., Rajarathnam, K. (2004) Dimer dissociation is essential for interleukin-8 (IL-8) binding to CXCR1 receptor. J. Biol. Chem. 279, 36175-36178.
25. Johnson, Z., Schwarz, M., Power, C. A., Wells, T. N., Proudfoot, A. E. (2005) Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol. 26, 268-274.
26. Springael, J. Y., Urizar, E., Parmentier, M. (2005) Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 16, 611-623.
27. Thelen, M., Muñoz, L. M., Rodrìguez-Frade, J. M., Mellado, M. (2010) Chemokine receptor oligomerization: functional considerations. Curr. Opin. Pharmacol. 10, 38-43.
28. Corbisier, J., Galès, C., Huszagh, A., Parmentier, M., Springael, J. Y. (2015) Biased signaling at chemokine receptors. J. Biol. Chem. 290, 9542-9554.
29. Schiraldi, M., Raucci, A., Muñoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., Thelen, M., Varani, L., Mellado, M., Proudfoot, A., Bianchi, M. E., Uguccioni, M. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551-563.
30. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., Shams, S. S., Yang, H., Varani, L., Andersson, U., Tracey, K. J., Bachi, A., Uguccioni, M., Bianchi, M. E. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528.
31. Venereau, E., Schiraldi, M., Uguccioni, M., Bianchi, M. E. (2013) HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol. Immunol. 55, 76-82.
32. Sebastiani, S., Danelon, G., Gerber, B., Uguccioni, M. (2005) CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. Eur. J. Immunol. 35, 746-756.
33. Paoletti, S., Petkovic, V., Sebastiani, S., Danelon, M. G., Uguccioni, M., Gerber, B. O. (2005) A rich chemokine environment strongly enhances leukocyte migration and activities. Blood 105, 3405-3412.
34. Kuscher, K., Danelon, G., Paoletti, S., Stefano, L., Schiraldi, M., Petkovic, V., Locati, M., Gerber, B. O., Uguccioni, M. (2009) Synergy-inducing chemokines enhance CCR2 ligand activities on monocytes. Eur. J. Immunol. 39, 1118-1128.
35. Koenen, R. R., von Hundelshausen, P., Nesmelova, I. V., Zernecke, A., Liehn, E. A., Sarabi, A., Kramp, B. K., Piccinini, A. M., Paludan, S. R., Kowalska, M. A., Kungl, A. J., Hackeng, T. M., Mayo, K. H., Weber, C. (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 15, 97-103.
36. Weber, C., Koenen, R. R. (2006) Fine-tuning leukocyte responses: towards a chemokine ‘interactome’. Trends Immunol. 27, 268-273.
37. Venetz, D., Ponzoni, M., Schiraldi, M., Ferreri, A. J., Bertoni, F., Doglioni, C., Uguccioni, M. (2010) Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int. J. Cancer 127, 2300-2312.
38. Von Hundelshausen, P., Koenen, R. R., Sack, M., Mause, S. F., Adriaens, W., Proudfoot, A. E., Hackeng, T. M., Weber, C. (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105, 924-930.
39. Crown, S. E., Yu, Y., Sweeney, M. D., Leary, J. A., Handel, T. M. (2006) Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding. J. Biol. Chem. 281, 25438-25446.
40. Degryse, B., Bonaldi, T., Scaffidi, P., Müller, S., Resnati, M., Sanvito, F., Arrigoni, G., Bianchi, M. E. (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152, 1197-1206.
41. Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., Oppenheim, J. J. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66.
42. Kew, R. R., Penzo, M., Habiel, D. M., Marcu, K. B. (2012) The IKKadependent NF-kB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J. Immunol. 188, 2380-2386.
43. Amara, A., Lorthioir, O., Valenzuela, A., Magerus, A., Thelen, M., Montes, M., Virelizier, J. L., Delepierre, M., Baleux, F., Lortat-Jacob, H., Arenzana-Seisdedos, F. (1999) Stromal cell-derived factor-1a associates with heparan sulfates through the first b-strand of the chemokine. J. Biol. Chem. 274, 23916-23925.
44. Drury, L. J., Ziarek, J. J., Gravel, S., Veldkamp, C. T., Takekoshi, T., Hwang, S. T., Heveker, N., Volkman, B. F., Dwinell, M. B. (2011) Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl. Acad. Sci U.S.A. 108, 17655-17660.
45. Penzo, M., Molteni, R., Suda, T., Samaniego, S., Raucci, A., Habiel, D. M., Miller, F., Jiang, H. P., Li, J., Pardi, R., Palumbo, R., Olivotto, E., Kew, R. R., Bianchi, M. E., Marcu, K. B. (2010) Inhibitor of NF-kB kinases a and b are both essential for high mobility group box 1-mediated chemotaxis [corrected]. [corrected] J. Immunol. 184, 4497-4509.
46. Campana, L., Bosurgi, L., Bianchi, M. E., Manfredi, A. A., Rovere- Querini, P. (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86, 609-615.
47. Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., Wong, T., Chiang, N. Y., Clark, S., Clark, R., Quintana, L., Gribling, P., Suto, E., Barck, K., Corpuz, R., Yao, J., Takkar, R., Lee, W. P., Damico-Beyer, L. A., Carano, R. D., Adams, C., Kelley, R. F., Wang, W., Ferrara, N. (2013) Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin. Cancer Res. 19, 4433-4445.
48. Hoppe, G., Talcott, K. E., Bhattacharya, S. K., Crabb, J. W., Sears, J. E. (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp. Cell Res. 312, 3526-3538.
49. Yang, H., Lundbäck, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M. E., Al-Abed, Y., Andersson, U., Tracey, K. J., Antoine, D. J. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18, 250-259.
50. Yang, H., Hreggvidsdottir, H. S., Palmblad, K., Wang, H., Ochani, M., Li, J., Lu, B., Chavan, S., Rosas-Ballina, M., Al-Abed, Y., Akira, S., Bierhaus, A., Erlandsson-Harris, H., Andersson, U., Tracey, K. J. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U.S.A. 107, 11942-11947.
51. Kim, K. Y., Lee, J. W., Park, M. S., Jung, M. H., Jeon, G. A., Nam, M. J. (2006) Expression of a thioredoxin-related protein-1 is induced by prostaglandin E(2). Int. J. Cancer 118, 1670-1679.
52. Matsuo, Y., Yodoi, J. (2013) Extracellular thioredoxin: a therapeutic tool to combat inflammation. Cytokine Growth Factor Rev. 24, 345-353.
53. Mahmood, D. F., Abderrazak, A., El Hadri, K., Simmet, T., Rouis, M. (2013) The thioredoxin system as a therapeutic target in human health and disease. Antioxid. Redox Signal. 19, 1266-1303.
54. Vezzoli, M., Castellani, P., Corna, G., Castiglioni, A., Bosurgi, L., Monno, A., Brunelli, S., Manfredi, A. A., Rubartelli, A., Rovere-Querini, P. (2011) High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid. Redox Signal. 15, 2161-2174.
55. Vénéreau, E., Ceriotti, C., Bianchi, M. E. (2015) DAMPs from cell death to new life. Front. Immunol. 6, 422.
56. Ortega-Gómez, A., Perretti, M., Soehnlein, O. (2013) Resolution of inflammation: an integrated view. EMBO Mol. Med. 5, 661-674.
57. Lotze, M. T., Tracey, K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342.
58. Andersson, U., Tracey, K. J. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162.
59. Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C. J., Wang, H., Roth, J., Warren, H. S., Fink, M. P., Fenton, M. J., Andersson, U., Tracey, K. J. (2004) Reversing established sepsis with antagonists of endogenous highmobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 101, 296-301.
60. Schierbeck, H., Lundbäck, P., Palmblad, K., Klevenvall, L., Erlandsson-Harris, H., Andersson, U., Ottosson, L. (2011) Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol. Med. 17, 1039-1044.
61. Porto, A., Palumbo, R., Pieroni, M., Aprigliano, G., Chiesa, R., Sanvito, F., Maseri, A., Bianchi, M. E. (2006) Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 20, 2565-2566.
62. Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., Pass, H. I., Gaudino, G., Carbone, M., Yang, H. (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290-3301.
63. Mortier, A., Gouwy, M., Van Damme, J., Proost, P. (2011) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654.
64. Graham, G. J., Locati, M., Mantovani, A., Rot, A., Thelen, M. (2012) The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 145, 30-38.